Global Next-Generation Antibody Therapeutics Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

Overview and Scope

Next-generation antibody therapeutics are advanced antibody-based drugs in structure, functionality, and therapeutic potential beyond traditional monoclonal antibodies. It treats several severe medical problems, including cancer, infectious infections, and immunological disorders.

Sizing and Forecast

The next-generation antibody therapeutics market size has grown rapidly in recent years. It will grow from $6.14 billion in 2023 to $6.9 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to monoclonal antibody success, rising prevalence of chronic diseases, approval of antibody-drug conjugates, growth of immunotherapy, gene therapy and antibodies.

The next-generation antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $10.41 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to biosimilar development, bispecific antibodies development, nanobody development, patient-centric approaches, immunomodulatory antibodies, expanded applications in autoimmune diseases, continuous manufacturing. Major trends in the forecast period include advancements in antibody engineering, digital technologies in antibody design, industry collaborations, advancements in drug delivery systems, real-world evidence in antibody development.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Segmentation & Regional Insights

The next-generation antibody therapeutics market covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

North America was the largest region in the next-generation antibody therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of chronic diseases is expected to propel the growth of the next-generation antibody therapeutics market going forward. Chronic diseases are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Next-generation antibody therapeutics have a therapeutic function for individuals with chronic illnesses that deliver more focused care, which would benefit patients’ outcomes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Therefore, the increasing prevalence of chronic diseases is driving the growth of the next-generation antibody therapeutics market.

Key Industry Players

Major companies operating in the next-generation antibody therapeutics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.

The next-generation antibody therapeutics market report table of contents includes:

1. Executive Summary

2. Next-Generation Antibody Therapeutics Market Characteristics

3. Next-Generation Antibody Therapeutics Market Trends And Strategies

4. Next-Generation Antibody Therapeutics Market – Macro Economic Scenario

5. Global Next-Generation Antibody Therapeutics Market Size and Growth

32. Global Next-Generation Antibody Therapeutics Market Competitive Benchmarking

33. Global Next-Generation Antibody Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Next-Generation Antibody Therapeutics Market

35. Next-Generation Antibody Therapeutics Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model